FDA Approves BRACAnalysis® CDx in Early-Stage Breast Cancer

On March 11, 2022, the U.S. Food and Drug Administration (FDA) approved Myriad Genetics, Inc.'s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) human epidermal growth factor receptor 2 (HER2)-negative, high-risk, early-stage breast cancer who may benefit from Lynparza® (olaparib) (AstraZeneca).

Read the Myriad Genetics, Inc. announcement.

Posted 3/14/2022